BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Jul 24, 2020
Politics, Policy & Law

Moderna says commercial path remains clear despite unfavorable patent ruling

Moderna isn’t aware of any IP barriers to its products, including its COVID-19 vaccine, after a PTAB decision on Thursday shaved more than $3 billion off its market cap. The Patent Trial and Appeal Board...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

Cross-border licensing company Everest, gene therapy play Freeline and oncology company Checkmate are the latest companies to enter the IPO queue, joining a long list of companies aspiring to go public in a season when...
BioCentury | Jul 14, 2020
Product Development

FDA encourages more representative cancer trials

Four FDA guidance documents lay out how to navigate the safety risks of enrolling historically under-represented patients in cancer clinical trials. FDA aims to boost enrollment of historically under-represented patient populations in cancer clinical trials...
BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

Real-world data isn’t just about post-market analysis of new drugs and vaccines. With the pandemic putting the benefits on display, epidemiologists are finding new ways to use the data, and new data sources, to support...
BioCentury | Apr 20, 2020
Finance

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

With the first three investments from a new fund launched in partnership with Italian charity Fondazione Telethon to invest in therapies for rare genetic diseases, Sofinnova Partners is aiming to build and expand the country’s...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

Arix Bioscience plc (LSE:ARIX) announced a series of senior management departures. CEO Joe Anderson has stepped down as CEO of the healthcare and life science investment company along with two undisclosed members of the senior...
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic. The Defense Research Advanced Projects...
BioCentury | Mar 4, 2020
Product Development

Hidden consequences of COVID-19: Why small biotechs can’t just wait this one out

It’s still anyone’s guess as to how long the COVID-19 outbreak will take to peak, let alone wane after that. But small biotechs could see knock-on effects that play out over a longer time frame...
BioCentury | Mar 4, 2020
Politics, Policy & Law

BIA calls U.K. trade agenda ‘sadly unambitious’

As the U.K. heads into trade talks with the EU and U.S., the U.K.’s BioIndustry Association has criticized the British government for an agenda that fails to reach beyond cooperation on safety with the EU...
Items per page:
1 - 10 of 589